KPV

Preclinical

Gut Health

A tripeptide derived from alpha-MSH with potent anti-inflammatory properties, particularly effective for gut inflammation and IBD.

Administration

Oral capsule or subcutaneous injection

Dosage Range

200-500 mcg daily

Mechanism of Action

KPV enters intestinal epithelial cells and interacts with inflammatory signaling pathways, inhibiting NF-kB activation and reducing pro-inflammatory cytokine production. It also modulates immune cell activity in the gut mucosa.

Clinical Benefits

Potent anti-inflammatory for gut

Reduces IBD symptoms

Supports gut barrier repair

Modulates immune response

Reduces systemic inflammation

Clinical Evidence

Preclinical studies demonstrate significant reduction in colitis severity and intestinal inflammation. Shows promise for IBD treatment with targeted gut anti-inflammatory action. Clinical trials in development.

Side Effects

Mild GI discomfort

Skin flushing

Fatigue (rare)

Contraindications

Pregnancy

Immunosuppressive therapy

Active infections

Related Peptides in Gut Health

Larazotide

A tight junction regulator peptide that reduces intestinal permeability (leaky gut) and shows promise for celiac disease treatment.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.